| Previous Close | 1.9000 |
| Open | 1.9000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 1.9000 - 1.9000 |
| 52 Week Range | 1.5000 - 3.2500 |
| Volume | 11 |
| Avg. Volume | 116 |
| Market Cap | 40.712M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
AVRA Medical Robotics, Inc. (the “Company”) (AVMR), an emerging company developing a proprietary software coded system that uses artificial intelligence and machine learning capabilities for the purpose of creating the next generation of fully autonomous medical robotic systems, announced today that its Chief Strategy Officer, D. Nikhil Shah, delivered a presentation at this year’s Annual Meeting of the Society of Robotic Surgery. Barry Cohen, Chairman and Chief Executive Officer of the Company, commented, “I was extremely pleased that we were able to share the AVRA story at this year’s meeting of the Society of Robotic Surgery.
As part of this research agreement, UCF engineering students under the direction of Electrical Engineering Professor Zhihua Qu, continue to assist AVRA with its research and development of autonomous medical robotics. AVRA’s robotics lab is located in Central Florida’s Research Park, in close proximity to UCF’s main campus.
AVRA Medical Robotics, Inc. (the “Company”) (AVMR), an emerging company that is creating the next generation of autonomous surgical robotics through the use of technologies such as artificial intelligence, machine learning and proprietary medical software architecture, announced today that it has retained The Horizon Phoenix Group and its principal Mr. Timothy K. Duggins as a regulatory consultant. The company entered into a four-year contract to conduct regulatory work on behalf of AVRA. The Horizon Phoenix Group has commenced its services on behalf of AVRA and has since initiated a dialogue with the Food and Drug Administration (FDA), prepared and filed an application for AVRA’s fully autonomous surgical robotic system with the FDA.
Over 95% of you have been with the AVRA TEAM and me for more than six years. Part of our strategic plan at AVRA was to provide a vehicle for individual investors to come into the firm at a low price usually available only to Private Equity, Institutional and High Stakes investors in this high-profile business, complete with a complex mix of Science, Math, Physics, Medicine, Surgery, Engineering all bound together by Hardware and Software talents. If you take a close look at the profiles of these people who help guide your company you will find the most accomplished achievers in their specialties in robotic surgery, including the surgeons who did the FIRST and the MOST prostate surgeries and the surgeon who works on the TINIEST Patients (infants under three weeks) with a medical robot.